Skip to content

Impact of the COVID-19 pandemic on the care of patients with malignant diseases - A retrospective, multicenter, non-interventional study of the East German Study Group for Hematology and Oncology (OSHO)

Impact of the COVID-19 pandemic on the care of patients with malignant diseases - A retrospective, multicenter, non-interventional study of the East German Study Group for Hematology and Oncology (OSHO) - COMA-19

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00027370
Enrollment
5145
Registered
2022-02-18
Start date
2021-06-30
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant diseases

Interventions

Group 1: Pseudonymized data sets, which were collected in the respective center according to the uniform basic oncology data set and its modules of the ADT and the GEKID, and reported to the responsib

Sponsors

Krukenberg Krebszentrum Halle
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Age > 18 years - newly diagnosed malignant tumors according to ICD-10 in 2018, 2019, and 2020

Exclusion criteria

Exclusion criteria: - Patients actively contradicting the consent for data collection

Design outcomes

Primary

MeasureTime frame
Number of newly diagnosed malignant tumors according to ICD-10 per month in 2020 compared to 2018 and 2019.

Secondary

MeasureTime frame
- Number of newly diagnosed malignancies, differentiated by individual tumor entity (monthly comparison between the years 2020, 2019 and 2018) - Interval between diagnosis and initiation of therapy, differentiated by individual tumor entity (monthly comparison between 2020, 2019, and 2018) - Stage of disease in solid neoplasms (TNM) at the time of diagnosis differentiated by individual tumor entities (monthly comparison between the years 2020, 2019, and 2018) - Outcome of disease (survival, event-free survival, recurrence incidence, and mortality incidence) at 1 and 2 years (comparison between new diagnoses in 2020, 2019, and 2018) - Influence of patient-related factors (age, sex, geographic residence based on zip code) on primary and above secondary endpoints. - Influence of disease-related factors (diagnosis, time of diagnosis, interval between diagnosis and initiation of therapy, TNM) on outcome.

Countries

Germany

Contacts

Public ContactHaifa Kathrin Al-Ali

Krukenberg Krebszentrum HalleUniversitätsklinikum Halle (Saale)

haifa.al-ali@uk-halle.de0345-557-7712

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026